Clinical features related to statin‐associated muscle symptoms Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • INTRODUCTION: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). METHODS: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. RESULTS: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. DISCUSSION: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537-537, 2019.


  • Ochs‐Balcom, Heather M
  • Nguyen, Ly Minh
  • Ma, Changxing
  • Isackson, Paul J
  • Luzum, Jasmine A
  • Kitzmiller, Joseph P
  • Tarnopolsky, Mark
  • Weisman, Michael
  • Christopher‐Stine, Lisa
  • Peltier, Wendy
  • Wortmann, Robert L
  • Vladutiu, Georgirene D

publication date

  • May 2019

has subject area